1. Home
  2. SFM vs IONS Comparison

SFM vs IONS Comparison

Compare SFM & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprouts Farmers Market Inc.

SFM

Sprouts Farmers Market Inc.

N/A

Current Price

$76.65

Market Cap

6.9B

ML Signal

N/A

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

N/A

Current Price

$75.65

Market Cap

13.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SFM
IONS
Founded
2002
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
13.5B
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
SFM
IONS
Price
$76.65
$75.65
Analyst Decision
Buy
Strong Buy
Analyst Count
12
22
Target Price
$112.92
$85.91
AVG Volume (30 Days)
2.9M
1.9M
Earning Date
05-25-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
41.60
21.71
EPS
5.31
N/A
Revenue
$8,806,159,000.00
N/A
Revenue This Year
$9.03
N/A
Revenue Next Year
$7.40
$66.43
P/E Ratio
$15.11
N/A
Revenue Growth
14.08
N/A
52 Week Low
$64.75
$23.95
52 Week High
$182.00
$86.74

Technical Indicators

Market Signals
Indicator
SFM
IONS
Relative Strength Index (RSI) 56.67 38.87
Support Level $64.88 $75.66
Resistance Level $82.28 $84.81
Average True Range (ATR) 3.34 2.77
MACD 0.90 -0.88
Stochastic Oscillator 76.29 24.03

Price Performance

Historical Comparison
SFM
IONS

About SFM Sprouts Farmers Market Inc.

Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: